Recommended Topic Related To:


"The combinations of anti-HIV drugs recommended for pregnant women do not appear in general to increase their children's risk for language delay, according to a study from a National Institutes of Health research network.

Children ex"...



Advice for the Patient

Information About Therapy With EPIVIR (lamivudine) : EPIVIR (lamivudine) is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using EPIVIR (lamivudine) . Patients should be advised that the use of EPIVIR (lamivudine) has not been shown to reduce the risk of transmission of HIV-1 to others through sexual contact or blood contamination.

Patients should be advised that the long-term effects of EPIVIR (lamivudine) are unknown at this time.

Patients should be advised of the importance of taking EPIVIR (lamivudine) with combination therapy on a regular dosing schedule and to avoid missing doses.

EPIVIR (lamivudine) should not be coadministered with drugs containing lamivudine or emtricitabine, including COMBIVIR (lamivudine/zidovudine) Tablets, EPZICOM (abacavir sulfate and lamivudine) Tablets, TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine), ATRIPLA (efavirenz, emtricitabine, and tenofovir), EMTRIVA (emtricitabine) or TRUVADA (emtricitabine and tenofovir) [see WARNINGS and PRECAUTIONS].

Redistribution/Accumulation of Body Fat: Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including EPIVIR (lamivudine) , and that the cause and long-term health effects of these conditions are not known at this time [see WARNINGS and PRECAUTIONS].

Differences in Formulations of EPIVIR (lamivudine) : Patients should be advised that EPIVIR (lamivudine) Tablets and Oral Solution contain a higher dose of the same active ingredient (lamivudine) as EPIVIR (lamivudine) -HBV Tablets and Oral Solution. If a decision is made to include lamivudine in the HIV-1 treatment regimen of a patient co-infected with HIV-1 and HBV, the formulation and dosage of lamivudine in EPIVIR (lamivudine) (not EPIVIR (lamivudine) -HBV) should be used [see Warnings and PRECAUTIONS].

Co-infection With HIV-1 and HBV: Patients co-infected with HIV-1 and HBV should be informed that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Patients should be advised to discuss any changes in regimen with their physician [see WARNINGS and PRECAUTIONS].

Risk of Pancreatitis: Parents or guardians should be advised to monitor pediatric patients for signs and symptoms of pancreatitis [see WARNINGS and PRECAUTIONS].

Sucrose Content of EPIVIR (lamivudine) Oral Solution: Diabetic patients should be advised that each 15-mL dose of EPIVIR (lamivudine) Oral Solution contains 3 grams of sucrose [see DESCRIPTION].

Last reviewed on RxList: 3/11/2011
This monograph has been modified to include the generic and brand name in many instances.


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.